Evaluation of Implantable Tibial Neuromodulation (TITAN 1) Feasibility Study (TITAN 1)
Primary Purpose
Overactive Bladder
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Medtronic Implantable Tibial Neuromodulation (TNM) System
Sponsored by
About this trial
This is an interventional device feasibility trial for Overactive Bladder
Eligibility Criteria
Primary Inclusion Criteria:
- Subjects 18 years of age or older
- Have a diagnosis for at least 6 months of OAB
- No OAB pharmacotherapy for 2 weeks prior to the baseline voiding diary
- Willing and able to accurately complete study diaries, questionnaires, attend visits, operate the system and comply with the study protocol
- Willing and able to provide signed and dated informed consent
Primary Exclusion Criteria:
- Have neurological conditions such as multiple sclerosis, clinically significant peripheral neuropathy or spinal cord injury
- Severe uncontrolled diabetes
- History of urinary retention within the previous 6 months
- Current symptomatic urinary tract infection
- Have primary stress incontinence or mixed incontinence where the stress component overrides the urge component
- Current urinary tract mechanical obstruction
- Have knowledge of planned magnetic resonance imaging (MRIs) or diathermy
- History of a prior implantable tibial neuromodulation system
- Skin lesions or compromised skin integrity at the implant site
- Anatomical defects, clinically significant edema or previous surgeries which precludes use of the device
- Previous pelvic floor surgery in the last 6 months
- Women who are pregnant or planning to become pregnant
- Characteristics indicating a poor understanding of the study or characteristics that indicate the subject may have poor compliance with the study protocol requirements.
- Any subject who is considered to be part of a vulnerable patient population.
- Concurrent participation in another clinical study that may add additional safety risks and/or confound study results.** **Subjects in concurrent studies can only be enrolled with permission from Medtronic.
Contact Medtronic's study manager to determine if the subject can be enrolled in both studies.
Sites / Locations
- Georgia Urology
- Urologic Research and Consulting
- FirstHealth Urogynecology
- Prisma Health
- Sanford Health
- Urology Partners of North Texas
- Milwaukee Urogynecology Ascension Medical Group
Outcomes
Primary Outcome Measures
To characterize the TNM device implant procedure
This information will be collected through a series of questions for participating investigators via a case report form at implant through the 14-day follow-up visit.
To characterize the TNM device initial system use
This information will be collected through programming and device data at implant through the 14-day follow-up visit.
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04873271
Brief Title
Evaluation of Implantable Tibial Neuromodulation (TITAN 1) Feasibility Study
Acronym
TITAN 1
Official Title
Evaluation of Implantable Tibial Neuromodulation (TITAN 1) Feasibility Study
Study Type
Interventional
2. Study Status
Record Verification Date
July 2022
Overall Recruitment Status
Completed
Study Start Date
May 11, 2021 (Actual)
Primary Completion Date
August 4, 2021 (Actual)
Study Completion Date
July 8, 2022 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
MedtronicNeuro
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Data Monitoring Committee
No
5. Study Description
Brief Summary
This is a prospective, multicenter, feasibility study to characterize the procedure for the implantable TNM device in subjects with overactive bladder.
Detailed Description
This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.)
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Overactive Bladder
7. Study Design
Primary Purpose
Device Feasibility
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
24 (Actual)
8. Arms, Groups, and Interventions
Intervention Type
Device
Intervention Name(s)
Medtronic Implantable Tibial Neuromodulation (TNM) System
Intervention Description
Tibial neuromodulation (TNM) devices are implantable devices that provide stimulation to the tibial nerve.
Primary Outcome Measure Information:
Title
To characterize the TNM device implant procedure
Description
This information will be collected through a series of questions for participating investigators via a case report form at implant through the 14-day follow-up visit.
Time Frame
14 days
Title
To characterize the TNM device initial system use
Description
This information will be collected through programming and device data at implant through the 14-day follow-up visit.
Time Frame
14 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Primary Inclusion Criteria:
Subjects 18 years of age or older
Have a diagnosis for at least 6 months of OAB
No OAB pharmacotherapy for 2 weeks prior to the baseline voiding diary
Willing and able to accurately complete study diaries, questionnaires, attend visits, operate the system and comply with the study protocol
Willing and able to provide signed and dated informed consent
Primary Exclusion Criteria:
Have neurological conditions such as multiple sclerosis, clinically significant peripheral neuropathy or spinal cord injury
Severe uncontrolled diabetes
History of urinary retention within the previous 6 months
Current symptomatic urinary tract infection
Have primary stress incontinence or mixed incontinence where the stress component overrides the urge component
Current urinary tract mechanical obstruction
Have knowledge of planned magnetic resonance imaging (MRIs) or diathermy
History of a prior implantable tibial neuromodulation system
Skin lesions or compromised skin integrity at the implant site
Anatomical defects, clinically significant edema or previous surgeries which precludes use of the device
Previous pelvic floor surgery in the last 6 months
Women who are pregnant or planning to become pregnant
Characteristics indicating a poor understanding of the study or characteristics that indicate the subject may have poor compliance with the study protocol requirements.
Any subject who is considered to be part of a vulnerable patient population.
Concurrent participation in another clinical study that may add additional safety risks and/or confound study results.** **Subjects in concurrent studies can only be enrolled with permission from Medtronic.
Contact Medtronic's study manager to determine if the subject can be enrolled in both studies.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Anne Miller
Organizational Affiliation
Medtronic
Official's Role
Study Director
Facility Information:
Facility Name
Georgia Urology
City
Marietta
State/Province
Georgia
ZIP/Postal Code
30060
Country
United States
Facility Name
Urologic Research and Consulting
City
Englewood
State/Province
New Jersey
ZIP/Postal Code
07631
Country
United States
Facility Name
FirstHealth Urogynecology
City
Hamlet
State/Province
North Carolina
ZIP/Postal Code
28345
Country
United States
Facility Name
Prisma Health
City
Greenville
State/Province
South Carolina
ZIP/Postal Code
29605
Country
United States
Facility Name
Sanford Health
City
Sioux Falls
State/Province
South Dakota
ZIP/Postal Code
57105
Country
United States
Facility Name
Urology Partners of North Texas
City
Arlington
State/Province
Texas
ZIP/Postal Code
76015
Country
United States
Facility Name
Milwaukee Urogynecology Ascension Medical Group
City
Milwaukee
State/Province
Wisconsin
ZIP/Postal Code
53211
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Evaluation of Implantable Tibial Neuromodulation (TITAN 1) Feasibility Study
We'll reach out to this number within 24 hrs